Translational research to realize the full potential of novel agents – an opportunity for vinflunine?

Anticancer therapy-induced adverse events: practicing damage control

“…In the review by Chow, the approval of vinflunine for transitional cell carcinoma of the urothelial tract is delineated as an example of a novel agent, a fluorinated vinca alkaloid with mitotic-inhibitory and tubulin-interacting activity [7,8]. Authors describe how its activity is currently being investigated in cancers of the breast and lung.…”